Oral Wegovy Weight Loss Pill Arrives in Israel
Translated & summarized from Mako by baba
The oral tablet form of the Wegovy weight loss drug will be available in Israeli pharmacies from Wednesday, October 26th. The pill leads to an average 16.6% weight loss after a year, though injections are more effective. Monthly costs will range from 640 to 1,260 shekels, with potential for subsidies.
The story in 5 lines · by baba
- The oral tablet version of Wegovy weight loss drug is launching in Israel on October 26th.
- The Wegovy pill results in an average 16.6% body weight loss after one year.
- Injectable Wegovy is more effective, achieving 20-25% weight loss.
- The monthly cost for Wegovy pills will be between 640 and 1,260 shekels.
- Gastrointestinal side effects like nausea are common but usually temporary.
The oral tablet version of the popular weight loss medication Wegovy will become available in Israeli pharmacies starting next Wednesday, October 26th. This development offers an alternative for patients seeking to manage excess weight who prefer not to use injections.
Clinical data indicates that the Wegovy pill leads to an average weight loss of approximately 16.6% of body weight after one year of treatment. This is more effective than the competing pill, Fendao, which was introduced to Israel about six weeks ago and results in an average weight loss of around 12.4%.
However, both oral tablet forms are still less effective than the injectable Wegovy, which can achieve an average weight reduction of 20% to 25% after a year. Despite this, many patients prefer taking a pill over regular injections, and it is estimated that oral versions could eventually capture about 50% of the weight loss drug market.
The monthly cost for Wegovy pills will range between 640 and 1,260 shekels. This price could be halved if health funds approve future funding or subsidies for the medication. Common side effects, similar to the injections, are primarily gastrointestinal, such as nausea and stomach discomfort, but these are usually temporary and subside after the body adjusts to the medication.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Only Mako so far.
